Measuring quality in surgical pathology is extremely difficult. In a way, it is like pornography: pathologists know quality when they see it, but they have been unable to define it. All pathologists know of laboratories and pathologists that they would consider high quality and those they would not. Yet defining criteria to measure and support their beliefs remains elusive.
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Gynecologic cytology has been through an agonizing decade as it continues to search to define acceptable standards of practice. Although the focus has been more on legal than quality assurance measures, the fundamental issues are the same: how does one define an error, and what are acceptable and unacceptable individual errors and overall error rates? The central causes of the pain of the last decade have been a massive underestimation of the error rate, extremely poor and inaccurate methods to measure this rate, and reluctance to face the fact that error is an unavoidable part of the task. [1] [2] [3] Nevertheless, there is much cause for hope in gynecologic cytology, with more accurate methods of defining errors becoming increasingly available, for both legal and quality assessment purposes.
Can surgical pathology benefit from the experience of gynecologic cytology? This article reviews the available literature on errors in surgical pathology and focuses on methodologic problems with this literature that previously have been dealt with in gynecologic cytology.
Methods
The literature was reviewed, and the data in that literature were assessed critically.
Reported errors were divided into the following categories: A false-negative error is a diagnosis of a lesion made on second review that was not made by the first review. A false-positive error is a diagnosis of a lesion that the reviewer thought was not present. An error of threshold refers to a difference of opinion, such as the difference between atypical ductal hyperplasia and ductal carcinoma in situ, that, while often clinically significant, does not reflect an error in identification of the lesion. Differences of type and grade refer to differences in tumor types and grading. Missed margins are positive margins that were missed. Errors that could not be assigned easily to one of these categories were assigned to the other category. While many errors are assigned easily to specific categories, others are more difficult. For example, I categorized missing the presence of muciphages for a diagnosis of a resolving colitis as a difference of diagnostic threshold rather than a false-negative diagnosis.
Results
The results of second review of surgical pathology case material are summarized in ❚Table 1❚. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] These studies can be divided into 3 categories based on the type of material that was reviewed: consecutive laboratory material, diagnostic biopsy material, and consultation material. In most studies, errors were divided into those that are clinically significant and those that are not. In some, the material was divided by organ or specimen type.
Overall error rates vary considerably. Overall reported error rates range from 0.5% to 43%, while clinically significant errors range from 0.25% to 24%. The largest error rates are reported consistently from neuropathology cases, [11] [12] [13] followed by gynecologic tract specimens 9, 10 and specimens from cytology cases and serosal surfaces. 9 In the reports in which specific diagnoses were listed, the errors can be divided into several types as shown in ❚Table 2❚. When so divided, the results of these studies show 3 major trends. In studies in which consecutive cases or biopsy specimens were examined, false-negative errors, completely missing the lesion, were the major if not the most common type of error, accounting for 40% and 43% of errors in 2 of the 3 series. In contrast, in all 3 series in which consultation material was reviewed, false-negative errors were rare, and false-positive, threshold, and typing and grading errors were more common. Finally, in all 3 neuropathology series, the vast majority of errors were in typing and grading.
Discussion
Only a few conclusions can be made from these studies. First, errors are not uncommon. Second, if one looks at all diagnostic material, false-negative errors, missing the lesion completely, appear to be the most common type of error. However, these errors are not detected when examining consultation material. This is not surprising since there usually would be little reason for patients whose lesions are not identified to be referred or seek second opinions. This is a major limitation of using this material. Third, false-negative errors are uncommon in neuropathologic material. This most likely relates not only to the fact that many of these studies are consultation driven but also to the low rate of nonlesional biopsies that are performed. Finally, some areas of surgical pathology have higher error rates than others.
Unfortunately, that is as far as one can go with the published data. In most other respects, the data are uninterpretable and misleading. There are several important reasons for this.
First, data are not presented in relation to disease incidence, and as such, the numbers from the different series are not comparable. Until the work of Krieger and Naryshkin 14 in 1994, error rates of 1% and 2% for gynecologic cytology were reported commonly. Indeed, if one asks a cytology laboratory director today what the overall error rate is in the laboratory in relation to all cases, the answer is almost always less than 2%. But this is meaningless because the number of negative cases is so much greater than the number of positive cases that the overall incidence will always appear low. Although there may be some variation in this number, one cannot determine the cause of the variation. It may reflect differences in error rate. However, it may simply reflect identical error rates but variation in the underlying disease rate. 1 In the surgical pathology literature, it is tempting to assume that the low error rates reported by Safrin and Bark 4 reflect better practice of pathology than those reported by Lind et al. 6 But if the material reviewed by Safrin and Bark 4 was primarily negative cases, these error rates may, in fact, be much higher than those reported by Lind et al, 6 who looked only at diagnostic biopsy specimens. As cytology has already learned, this overall global error rate is almost useless, does not reflect the true false-negative rate, is not comparable between laboratories, and can easily be used to the plaintiff's advantage. The most accurate false-negative rates for gynecologic cytology reported to date are all higher than 20%, [15] [16] [17] which is quite different from 1% to 2%. Second, the sensitivity of the review process is critical. In gynecologic cytology, nonblinded review of negative cases has a sensitivity of less than 30%. 3 In the 1 article that mentions this issue, Whitehead et al 5 indicate that the sensitivity of review was only 53% to 67%. Obviously, if one wishes to measure the true error rate, one must use blinded review, and one must account for the error in the review process, the details of which have been described exhaustively for gynecologic cytology. [1] [2] [3] The only conclusion that one can make from the current surgical pathology literature is that the currently reported "error rates" almost certainly underestimate the true error rate.
Third, "gold standards" remain undefined. While it is always tempting to use the second review as the gold standard, this is problematic. Indeed, this has been a major issue in gynecologic cytology, especially when studying new technologies. 18 In surgical pathology, several studies point out that in some cases, the initial diagnosis and not the review diagnosis eventually turned out to be correct. In some cases, this conclusion is reached by a third review, 7 in others by clinical follow-up. 9 If one uses a third reviewer, who should that be? The fact remains that many differences in diagnostic threshold are not verifiable, and, in fact, the generally accepted expert opinion for carcinoma is not 100% specific when follow-up material is used as a gold standard. 19 What does the experience in gynecologic cytology say for measuring and reporting errors in surgical pathology? The most important message is that this task is very, very difficult. Surgical pathology is not burdened with the brutal screening task that cytology is. Nevertheless, it still remains a screening task, and the available data suggest that screening is one of the major sources-if not the most important source-of error in the task. Appropriate sampling will be key. Practices that rely on review of abnormal cases alone will not be able to evaluate false-negative errors. Review of every case is enormously burdensome and certainly is not affordable in our current fiscal environment. Review of a random sample focuses a disproportionate amount of effort on material that has a very low rate of abnormality, and almost certainly review of this material has a very low vigilance rate. 20 Truly measuring the overall error rate most likely will never be accomplished on a routine basis. Development of appropriate surrogates, such as examining only diagnostic biopsy specimens, and recognizing the limitations of others, such as examining only consultation material, will be necessary first steps. Perhaps surrogate markers such as those used in gynecologic cytology (eg, the ratio of atypical squamous cells of undetermined significance/squamous intraepithelial lesion 21 ) may be of value in surgical pathology as well. For example, what exactly is the appropriate ratio of atypical ductal hyperplasia to carcinoma? Another common surrogate marker may simply be the overall incidence of a disease, such as carcinoma, in a particular specimen type, 12 Neuropathology consultation material 0 (0) 0 (0) 0 (0) 64 (100) 0 (0) 0 (0) 64 Aldape et al 13 Neuropathology such as prostate needle biopsy specimens. While changes in this incidence may result from several different sources, one possible source is diagnostic error. Consensus on what constitutes an error and what type of error it is also will be difficult. Consensus still has not been achieved in gynecologic cytology. Consensus in surgical pathology will be more difficult, simply because the task is more complex. Although there are infections and other tumors, the major focus in gynecologic cytology is identifying squamous lesions. Errors in surgical pathology, with numerous neoplastic and nonneoplastic lesions, typing, staging, and margin status, certainly will be more difficult to quantify into a single number. Indeed, the current trend of reporting a single number and not making the simple and fundamental distinction between sensitivity and specificity highlights how far surgical pathology has to go.
But these are my opinions. The surgical pathology community has a choice. It does not have to address these issues now. Addressing them will take enormous effort. But error rates in surgical pathology are out there, and no matter how inaccurate and misleading they are, clinicians, patients, insurers, and lawyers will be using them to make decisions about where to send material and how and when to litigate. Cytologists already have been through a decade of inadequate reimbursement and legal nightmares based almost entirely on unrealistic expectations created by poor data and inappropriate data analysis. It is up to the surgical pathology community whether it wishes to follow in these particular footsteps.
